H.C. Wainwright assumed coverage of Madrigal Pharmaceuticals (MDGL) with a Buy rating and $500 price target The firm believes the company is “uniquely positioned to dominate” the emerging metabolic dysfunction-associated steatohepatitis treatment landscape through its thyroid hormone receptor-beta platform.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDGL:
- Madrigal Pharmaceuticals price target raised to $554 from $390 at TD Cowen
- Madrigal Pharmaceuticals: Pioneering MASH Treatment with Rezdiffra’s European Market Breakthrough
- Madrigal Pharmaceuticals price target raised to $485 from $483 at Citizens JMP
- Madrigal gets conditional marketing authorization for Rezdiffra from EC
- Buy Rating Affirmed for Madrigal Pharmaceuticals Amid Market Expansion Opportunities